💰 The savings per batch can reach $100,000, helping to align therapy costs with payer budgets.
🔬 The team achieved impressive yields, matching traditional methods, but with greater efficiency. The innovation also simplifies raw material sourcing and reduces additional assays.
⚙️ Key improvements include salt addition to boost filtration.
Introduction:
The article discusses a significant advancement by Regeneron in the manufacturing process of adeno-associated vectors (AAVs). By integrating single-use chromatographic clarification and eliminating the use of endonuclease in downstream purification, this novel approach promises to enhance efficiency and reduce costs in the production of vital gene therapy delivery vehicles.
- Regeneron has implemented single-use chromatographic clarification in its commercial-scale AAV manufacturing process, allowing for the elimination of endonuclease.
- This modification is projected to save approximately $100,000 per 500-L batch, thereby significantly lowering manufacturing costs.
- The research indicates that yields of AAVs can match or surpass the quality of traditional methods even without endonuclease treatment.
- Host cell DNA levels were dramatically reduced, achieving up to 3 logs reduction for rAAV9, comparable to conventional purification methods.
- The study suggests that adjusting the harvest buffer with salt significantly improves filtration throughput and prevents clogging of chromatography filters.
Conclusion:
The elimination of endonuclease in AAV processing by Regeneron not only enhances the efficiency of gene therapy production but holds the promise of reducing therapeutic costs, which is essential for aligning with payer budgets. Future advancements in this area may further optimize scalability and availability of gene therapies.
